Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Duolingo Inc (DUOL) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

Duolingo stock trades at $124.76, down 3.99% on the day, as the language learning platform shows strong fundamental performance with revenue reaching $1.04 billion in 2025 and net income of $414 million. The company has consistently beaten earnings expectations in recent quarters, with technical indicators showing a bullish trend despite some overbought signals. Recent news highlights AI integration improvements and user growth potential, with the stock trading above analyst consensus price targets.

Duolingo presents a compelling growth story with robust profitability metrics and expanding user base, though valuation remains elevated. Key risks include AI disruption concerns and competitive pressures in the edtech space. The current price offers potential upside to high analyst targets but requires monitoring of user growth sustainability and margin trends.